Pure Global
NCT06323928

A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-finding Trial of Lu AG09222 for the Prevention of Migraine in Participants With Unsuccessful Prior Preventive Treatments
H. Lundbeck A/S·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Migraine
Drug/Device/Intervention
Lu AG09222
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
H. Lundbeck A/S
Location
Clermont,Maitland,Tampa,Ames,Cary,Raleigh,Mount Pleasant,Bristol, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Apr 01, 2024
End date
Sep 30, 2025
Enrollment
498 participants
Primary outcome

Change From Baseline in the Number of Monthly Migraine Days (MMDs)

Summary

The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help
 prevent migraines. People who join this trial have already tried 2 to 4 other available
 medications to prevent their migraines, but these medications have not helped them.

ICD-10 classifications
MigraineOther migraineMigraine, unspecifiedComplicated migraineHeadache
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06323928
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06323928 through Pure Global AI's free database. This Phase 2 trial is sponsored by H. Lundbeck A/S and is currently Recruiting. The study focuses on Migraine. Target enrollment is 498 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.